



Cite this: *Dalton Trans.*, 2015, **44**, 1161

Gold(i) thiotetrazolates as thioredoxin reductase inhibitors and antiproliferative agents†

Tatiana V. Serebryanskaya,^{a,b,c} Alexander S. Lyakhov,^b Ludmila S. Ivashkevich,^b Julia Schur,^a Corazon Frias,^d Aram Prokop^d and Ingo Ott^{*a}

Gold(i) complexes with phosphane and thiotetrazolate ligands were prepared and investigated as a new type of bioactive gold metallodrugs. The complexes triggered very efficient inhibition of the enzyme thioredoxin reductase (TrxR), which is an important molecular target for gold species. Strong cytotoxic effects were observed in MDA-MB-231 breast adenocarcinoma and HT-29 colon carcinoma cells, and the complexes also caused strong effects in vincristine resistant Nalm-6 leukemia cells. Cellular uptake studies showed elevated cellular gold levels for complexes containing a triphenylphosphane ligand, whereas trifurylphosphane analogues accumulated at significantly lower cellular concentrations.

Received 8th October 2014,
Accepted 4th November 2014

DOI: 10.1039/c4dt03105a

www.rsc.org/dalton

Introduction

The therapeutic use of gold and its complexes dates back to thousands of years ago and was also a hot topic in alchemy during medieval ages and the Renaissance.¹ However, the elaboration of gold based antiproliferative agents is a relatively young and intensively developing area of medicinal and pharmaceutical chemistry.^{2–5} The precise mechanisms of anti-tumor activity of gold compounds have not been completely understood. As a result of a series of mechanistic studies it was suggested that binding of gold to the selenoenzyme thioredoxin reductase (TrxR) leads to its inhibition, which results in the alteration of mitochondrial functions, increased formation of reactive oxygen species and finally causes cell death *via* apoptosis.^{6,7} Both gold(i) and gold(III) derivatives were found to be efficient inhibitors of thioredoxin reductase,⁶ yet gold(III) based complexes are nowadays considered as prodrugs that are reduced before binding to give gold(i) species.⁸

The choice of ligands appears to be one of the most challenging tasks in the design of novel gold based antitumor agents. Owing to the “soft acidic” nature of gold(i), its coordination compounds are highly prone to rapid metabolic trans-

formations *via* interaction with numerous sulfur containing proteins and peptides *in vivo*.² Therefore, stability is a crucial point in the design of gold(i) species, and usually, typical “soft bases” such as phosphorus- and sulphur-containing nucleophiles are utilized as ligands to enhance the stability of the resulting gold(i) complexes under physiological conditions. Gold(i) phosphane complexes are the most frequently investigated group of gold based compounds.^{3,9–15} Many of them, including auranofin (Fig. 1) and chlorido gold(i) phosphane (1, Fig. 1) complexes, were shown to be effective antiproliferative agents and potent TrxR inhibitors.^{6,7,16}

Here we report on the synthesis and biological evaluation of a new series of tetrazole-containing gold(i) phosphane complexes (2, Fig. 1). Being rather new ligands in bioinorganic chemistry, tetrazole derivatives have been gaining increasing attention in recent years due to the development of more efficient synthesis methods.¹⁷ Moreover, the tetrazole ring is a well known bioisoster of the carboxylic group and several tetrazole-containing platinum complexes have earlier been reported as possessing a promising antiproliferative profile and low toxicity *in vivo*.^{18–20}

Gold(i) complexes with polynitrogen-containing azoles have been relatively little studied so far. Among them, mixed-ligand phosphane gold(i) 5-thiotetrazolates 2 are among the most investigated groups.²¹ The obvious structural analogy between this group of gold(i) complexes and auranofin makes them interesting subjects for antitumor drug design. Despite this fact, there have been to date no data reported in the literature on their antiproliferative or other biological effects. In order to elucidate a possible structure–activity relationships within this group of gold(i) complexes, a panel of (phosphane)gold(i) 1-R-5-thiotetrazolates has been synthesized and characterized by means of spectroscopic and structural methods. Their antipro-

^aInstitute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstrasse 55, 38106 Braunschweig, Germany.
E-mail: ingo.ott@tu-bs.de

^bResearch Institute for Physical Chemical Problems of the Belarusian State University, 14 Leningradskaya st., 220030 Minsk, Belarus

^cInstitute of Chemistry, Saint Petersburg State University, 198504 Sary Petergof, Russian Federation

^dDepartment of Paediatric Oncology, Children's Hospital Cologne, Amsterdamer Strasse 59, 50735 Cologne, Germany

†CCDC 1027451. For crystallographic data in CIF or other electronic format see DOI: 10.1039/c4dt03105a



Fig. 1 Examples of gold(i) phosphane complexes.

Table 1 Main crystal data and structure refinement details for complex **2e**

| | |
|---|--|
| Formula | C ₁₉ H ₁₄ AuN ₄ O ₃ PS |
| Formula weight | 606.34 |
| <i>T</i> /K | 296(2) |
| Crystal system | Monoclinic |
| Space group | <i>C2/c</i> |
| Crystal size/mm | 0.35 × 0.34 × 0.12 |
| <i>a</i> /Å | 13.79810(10) |
| <i>b</i> /Å | 13.08130(10) |
| <i>c</i> /Å | 22.1996(3) |
| β /° | 91.0696(5) |
| <i>V</i> /Å ³ | 4006.27(7) |
| <i>Z</i> | 8 |
| <i>D_c</i> /g cm ⁻³ | 2.011 |
| μ /mm ⁻¹ | 7.557 |
| Reflections | 5371 |
| Restraints | 0 |
| Parameters | 262 |
| <i>R</i> ₁ / <i>wR</i> ₂ [<i>I</i> > 2σ(<i>I</i>)] | 0.0210/0.0484 |
| <i>R</i> ₁ / <i>wR</i> ₂ [all data] | 0.0283/0.0505 |
| Goodness-of-fit | 1.004 |

phosphane C–P–C valence angles, lying in a range of 103.83(12)–107.55(12)°, are smaller than the tetrahedral one. These geometric features are very similar to those in complexes **2a** and **2b**. The fragment AuPR₃ (R = 2-furyl) displays a distorted non-propeller-like structure due to the large variation in dihedral angles Au–P–C–C [–5.8(3), 8.1(3) and 16.6(4)°].

As for the tetrazole ring geometry, it is typical of 1*H*-tetrazoles in the three complexes **2a**, **2b** and **2e** (see Table 2), with the shortest bond N2–N3 and remaining bond distances lying in rather narrow ranges. In the crystal structure of complex **2e**, there are non-classic intermolecular hydrogen bonds C35–H35...O11^b between two neighboring complex molecules [symmetry transformation: (*b*) –*x*, *y*, –*z* + 1/2; hydrogen bond geometry: H35...O11^b 2.55 Å, C35...O11^b 3.424(3) Å, C35–H35...O11^b 157°]. These bonds form dimeric entities comprising R₂²(14) hydrogen-bonded rings (Fig. 2b).

The complex molecules are bonded into dimeric units through very weak aurophilic bonding,²⁶ with a separation of the gold atoms Au1...Au1^c of 3.3892(5) Å (symmetry transformation as in Fig. 2c). These units are connected *via* the above mentioned hydrogen bonds to give polymeric chains running along the *a* axis.

TrxR and GR inhibition activity

As mentioned above, inhibition of the selenoenzyme thio-redoxin reductase (TrxR) is considered to be an important mechanism of bioactivity of gold(i) species.^{3,6,7} Therefore, the potential of tetrazole-based gold(i) complexes to inhibit TrxR was studied on isolated rat liver TrxR using the DTNB (dithio-bisnitrobenzoic acid) reduction assay. As far as selenocysteine is considered to be the relevant binding site for gold complexes, another structurally and functionally similar disulfide reductase, *i.e.* glutathione reductase (GR, from yeast), was included in the test as a reference. Instead of selenocysteine, GR contains a cysteine residue in its active site and thus can




Fig. 2 (a) Complex **2e**, with the atom numbering scheme and displacement ellipsoids drawn at the 30% probability level; (b) hydrogen-bonded dimer in the crystal structure of **2e**; (c) dimeric unit formed by aurophilic bonding in the crystal structure of **2e** [symmetry transformation: (c) 1 – *x*, *y*, 1/2 – *z*].

Table 2 Some geometric features (Å, °) of complexes **2a**, **2b** and **2e**

| Compound | 2a ^a | 2b ^a | 2e |
|-----------|------------------------|------------------------|-----------|
| Au1–P1 | 2.261(1) | 2.265(2) | 2.2475(6) |
| Au1–S1 | 2.325(1) | 2.304(2) | 2.3051(7) |
| P1–Au1–S1 | 170.11(3) | 172.68(5) | 170.93(3) |
| C5–S1–Au1 | 97.5(1) | 105.3(2) | 99.28(9) |
| S1–C5 | 1.740(4) | 1.733(7) | 1.726(3) |
| N1–C5 | 1.342(5) | 1.346(9) | 1.350(3) |
| N1–N2 | 1.354(5) | 1.378(8) | 1.361(3) |
| N2–N3 | 1.289(5) | 1.295(9) | 1.285(4) |
| N3–N4 | 1.354(5) | 1.366(8) | 1.359(4) |
| N4–C5 | 1.331(5) | 1.346(8) | 1.326(3) |

^a From ref. 24.



Table 3 Antiproliferative activity and inhibition activity against TrxR and GR of gold(i) phosphane complexes **1a–b** and **2a–e**, n.d.: not determined

| Compound | IC ₅₀ (μM) | | Selectivity GR/TrxR (<i>x</i> -fold) | IC ₅₀ (μM) | |
|-----------|-----------------------------|-------------------------|--|-----------------------|-------------------------|
| | TrxR | GR | | MDA-MB-231 | HT-29 |
| 1a | 0.256 ± 0.002 ²⁷ | 4.2 ± 0.7 ²⁷ | 16 | 9.5 ± 0.7 | 4.2 ± 0.9 ¹⁰ |
| 1b | 0.207 ± 0.021 | n.d. | | 9.9 ± 0.7 | 10.0 ± 1.8 |
| 2a | 0.037 ± 0.010 | 0.97 ± 0.25 | 26 | 7.9 ± 1.9 | 12.0 ± 2.7 |
| 2b | 0.046 ± 0.012 | 0.55 ± 0.04 | 12 | 7.8 ± 2.0 | 10.2 ± 1.5 |
| 2c | 0.165 ± 0.065 | 0.66 ± 0.19 | 4 | 8.9 ± 1.1 | 8.6 ± 0.7 |
| 2d | 0.033 ± 0.005 | 0.43 ± 0.05 | 13 | 8.5 ± 1.5 | 13.3 ± 2.9 |
| 2e | 0.053 ± 0.001 | 0.51 ± 0.07 | 10 | 9.3 ± 0.2 | 11.5 ± 1.7 |
| 3a | n.d. | n.d. | — | >100 | >100 |
| 3b | n.d. | n.d. | — | >100 | >100 |
| 3c | n.d. | n.d. | — | >100 | >100 |

be used to check the specificity of TrxR inhibition by the tested compounds.^{28,29}

According to the results given in Table 3, tetrazole-containing gold(i) complexes turned out to be very effective inhibitors of TrxR with IC₅₀ values in the low nanomolar range. With the exception of **2c**, all complexes showed IC₅₀ values in the range 30–55 nM and at least 10-fold selectivity for inhibition of TrxR over GR. In all cases **2a–e** were more effective enzyme inhibitors than the respective chlorido complexes **1a** and **1b**.


Antiproliferative activity

Antiproliferative activity of thiotetrazole-containing gold(i) complexes **2a–e** against two human cancer cell lines (MDA-MB-231 and HT-29) was assessed using the crystal violet assay. Chlorido(triphenylphosphane)gold(i) (**1a**) and chlorido-[tri(2-furyl)phosphane]gold(i) (**1b**) were included in the test as positive controls. According to the results (Table 3), the tetrazole-containing complexes **2a–e** demonstrate considerable antiproliferative activity against both human cancer cell lines with IC₅₀ values found in the micromolar or low micromolar range (approx. 8.0–13.0 μM). These values are comparable to those of the positive controls and the platinum anticancer drug cisplatin (IC₅₀ values of 7.0 μM in HT-29 cells³⁰ and 4.0 μM in MDA-MB-231 cells³¹). The metal-free thiotetrazole derivatives **3a–c** were investigated as negative controls and showed no inhibition of tumor cell proliferation.

Cellular uptake

In order to evaluate the extent of cellular uptake, we measured the gold content in HT-29 cells exposed to 10.0 μM (approx. equal to the IC₅₀ calculated for this cell line) solutions of the tested compounds for a period of 1, 4 and 8 h by a method based on high resolution continuum source atomic absorption spectroscopy (HR-CS AAS).^{32,33} Results were corrected for the respective protein contents of the samples and are presented in Fig. 3 as nmol gold per milligram cellular protein. Besides, based on certain biophysical parameters of HT-29 cells,³² the nmol Au per mg protein values obtained were used to estimate the respective intracellular molar concentrations.

As shown in Fig. 3, the highest values of intracellular accumulation were observed for triphenylphosphine gold(i)

**Fig. 3** Cellular gold content of HT-29 cells exposed to 10 μM of gold(i) complexes **2a–e**.

complexes **2a–c**. The content of gold in HT-29 cells reached by these complexes after 1 h of exposure correlated to intracellular concentrations of 150 (**2a**), 265 (**2b**) and 210 (**2c**) μM, respectively. Taking into account the exposure concentration of 10.0 μM, one can conclude that for these complexes at least 15-fold accumulation can be achieved already within the first hour of the experiment. This is markedly higher than the 8-fold accumulation reported for the chlorido derivative **1a** after 6 h of exposure.¹⁰ Drastically lower levels of cellular uptake were found for [tri(2-furyl)phosphane]gold(i) complexes **2d** and **2e**, which can be explained by their lower lipophilicity. Intracellular concentrations of 10 and 40 μM observed for **2d** and **2e**, respectively, after 1 h of exposure are 7–15 times lower in comparison with their triphenylphosphane-based analogs **2a** and **2b**.

Antiproliferative activity in a resistant cell line

Resistance to therapeutic agents is a major problem in current tumor chemotherapy. Hence, the development of drugs that can overcome drug resistance in tumor tissues is of major interest. Here we used wild type and vincristine resistant






Fig. 4 Effects of **2a** (top) and **2d** (bottom) on DNA fragmentation in wild type and vincristine resistant Nalm-6 cells after 72 h of exposure; Co: control; DMSO: cells treated with the same amount of DMSO; VCR: vincristine (20 nM).

NALM-6 cells, which overexpress the drug efflux pump *p*-glycoprotein,³³ to evaluate the possible overcoming of drug resistance by the gold complexes under study. Complexes **2a** and **2d** were selected for these experiments as examples with high (**2a**) and low (**2d**) cellular uptake but comparable toxicity and TrxR inhibitory potential (see above). Apoptosis induction was assessed as DNA fragmentation in the cells.

In fact, both **2a** and **2d** triggered strong effects in wild type and vincristine resistant NALM-6 cells already in low micromolar concentrations (>50% DNA fragmentation at 1.0 μM with **2a** and 2.5 μM with **2d**), which clearly demonstrated that both complexes could overcome *p*-glycoprotein related multidrug resistance (see Fig. 4).

Conclusions

A series of different gold(i) phosphane complexes with thiotetrazolato ligands was prepared and biologically evaluated. The crystal structure of complex **2e** showed the expected linear coordination geometry around the gold center. Interestingly, dimers were formed by intermolecular hydrogen bonding between the furane moieties.

Complexes **2a–e** turned out to be very effective inhibitors of the enzyme TrxR. Comparison with the respective chloride

analogues **1a** and **1b** indicated that the thiotetrazolato ligand was important for this effect. The lowest activity in the series **2a–e** was observed for **2c**, which contains an aliphatic side chain with a tertiary nitrogen at the thiotetrazolato ligand. Notably, strong TrxR inhibition with thiophenolate containing gold(i) carbene complexes was also observed in a previous study.³⁴ However, the enhanced activity against TrxR did not translate into elevated cytotoxicity since complexes **2a–e** were of comparable activity with **1a** and **1b** in cell proliferation assays.

Cellular uptake studies showed a very high accumulation of the triphenylphosphane containing complexes **2a–c**, whereas the triphenylfurane analogues **2d** and **2e** were found at significantly lower levels in the cells. It can be speculated that possible dimer formation by hydrogen bonding of the trifurylphosphane moiety might contribute to this effect besides differences in the lipophilicity. It should be mentioned that we observed higher cellular accumulation of triphenylphosphane gold complexes compared to trialkylphosphane derivatives in a number of recent studies^{10,11,35} and that lipophilicity is generally considered to be an important parameter for cellular uptake of gold phosphane species.³⁶

Importantly, selected compounds **2a** and **2d** showed decent activity in *p*-glycoprotein overexpressing vincristine-resistant Nalm-6 cells, which indicates that this type of gold compounds might be useful for the design of resistance overcoming drugs.

In summary, gold complexes with thiotetrazolate represent a new promising class of gold species, which trigger important biological effects such as TrxR inhibition and cytotoxicity.

Experimental

Materials and methods

All reagents and solvents were used as received from Sigma, Aldrich, or Acros Organics. ¹H and ¹³C NMR spectra were recorded on a Bruker DRX-400 AS NMR system. ESI(+) mass spectra were recorded on a Bruker microTOF instrument using dichloromethane as a solvent. The purity of the target compounds (>95%) was confirmed by elemental analysis. For all compounds undergoing biological evaluation, the experimental values differed less than 0.5% from the calculated ones.

IR spectra of powder samples were registered on a Nicolet Thermo Avatar 330 spectrometer using a Smart Diffuse Reflection accessory in the range of 4000–400 cm^{−1}. The TG and DSC curves were obtained with a NETZSCH STA 429 thermoanalyzer under a dynamic nitrogen atmosphere (heating rate of 10 K min^{−1}, aluminum oxide, mass 5–6 mg and temperature range from room temperature to 600 °C).

Synthesis of gold(i) complexes **2a–e**

Compounds **2a–c** were obtained using the following general procedure. 0.5 mmol (248 mg) of chlorido(triphenylphosphane)gold(i) and 0.5 mmol of the corresponding 1-*R*'-5-thio-



tetrazole **3a–c** were dissolved in 20 ml of CH_2Cl_2 . Triethylamine (0.1 mL) was added dropwise to the prepared solution, and the mixture was stirred overnight at room temperature. Then the mixture was evaporated to dryness, and the residue was dissolved in hot THF. After cooling to room temperature, needle-like crystals of triethylammonium chloride formed and were separated by filtration. The filtrate was evaporated again, and the solid residue was recrystallized from CH_2Cl_2 –hexane (**2a** and **2b**) or acetonitrile (**2c**) to obtain the colorless product.

(1-Methyltetrazol-5-ylthiolato)(triphenylphosphane)gold(I) (**2a**). Yield (from CH_2Cl_2 –hexane): 235 mg (82%). *Anal.* Calc. for $\text{C}_{20}\text{H}_{18}\text{N}_4\text{PSAu}$: C, 41.82; H, 3.16; N, 9.75; S, 5.58. Found: C, 42.31; H, 3.30; N, 9.97; S, 5.32%. MS (ESI^+ , 100 V, CH_2Cl_2 , m/z): 575.07 $[\text{M} + \text{H}]^+$; 721.15 $[\text{Au}(\text{PPh}_3)_2]^+$. DSC/TG: 189–190 °C (mp); 282 °C (T_{max} , exothermal dec.). ^1H NMR [400 MHz, CDCl_3 , δ (ppm)]: 7.62–7.47 (m, 15H, C_6H_5); 3.96 (s, 3H, CH_3). ^{13}C NMR [100 MHz, CDCl_3 , δ (ppm), J (Hz)]: 158.0 (s, $\text{C}(5)^{\text{tz}}$); 134.3 (d, $^2J(\text{C},\text{P}) = 13.8$, *ortho*-C from PPh_3); 131.9 (d, $^4J(\text{C},\text{P}) = 2.5$, *para*-C from PPh_3); 129.3 (d, $^3J(\text{C},\text{P}) = 11.7$, *meta*-C from PPh_3); 128.9 (d, $^1J(\text{C},\text{P}) = 59.0$, *ipso*-C from PPh_3); 34.0 (s, CH_3^{tz}). FT-IR (ν , cm^{-1}): 3054 (s), $\nu(\text{CH}_{\text{aryl}})$; 2942 (m), $\nu(\text{CH}_{\text{alkyl}})$; 1478 (s), $\nu(\text{CC}_{\text{aryl}})$; 1436 (vs), 1377 (s), $\delta(\text{CH}_{\text{aryl}}) + \delta(\text{CH}_{\text{alkyl}})$; 1332 (m), 1313 (m), 1264 (s), 1222 (m), 1162 (s), $\nu(\text{N}=\text{N}_{\text{tz}}) + \nu(\text{N}-\text{N}_{\text{tz}})$; 1101 (s), 1077 (m), 1026 (m), 996 (m), 969 (m), $\delta(\text{CN}_4) + \delta(\text{C}_6\text{H}_5)$; 749 (vs), $\nu(\text{C}-\text{P})$; 693 (vs), $\nu(\text{C}-\text{S})$.

(1-Phenyltetrazol-5-ylthiolato)(triphenylphosphane)gold(I) (**2b**). Yield (from CH_2Cl_2 –hexane): 290 mg (91%). *Anal.* Calc. for $\text{C}_{25}\text{H}_{20}\text{N}_4\text{PSAu}$: C, 47.18; H, 3.17; N, 8.80; S, 5.04. Found: C, 47.32; H, 3.22; N, 9.08; S, 4.88%. MS (ESI^+ , 100 V, CH_2Cl_2 , m/z): 637.09 $[\text{M} + \text{H}]^+$; 721.15 $[\text{Au}(\text{PPh}_3)_2]^+$. DSC/TG: 195–196 °C (mp); 213 °C (T_{max} , exothermal dec.). ^1H NMR [400 MHz, CDCl_3 , δ (ppm)]: 7.76–7.74 (m, 2H, CH from $\text{C}_6\text{H}_5^{\text{tz}}$); 7.59–7.40 (m, 18H, CH from $\text{C}_6\text{H}_5^{\text{tz}}$ and PPh_3); 3.96 (s, 3H, CH_3). ^{13}C NMR [100 MHz, CDCl_3 , δ (ppm), J (Hz)]: 158.1 (s, $\text{C}(5)^{\text{tz}}$); 135.2 (s, *ipso*-C from $\text{C}_6\text{H}_5^{\text{tz}}$); 134.3 (d, $^2J(\text{C},\text{P}) = 13.8$, *ortho*-C from PPh_3); 131.9 (s, *meta*-C from $\text{C}_6\text{H}_5^{\text{tz}}$); 131.9 (d, $^4J(\text{C},\text{P}) = 2.3$, *para*-C from PPh_3); 129.3 (d, $^3J(\text{C},\text{P}) = 11.7$, *meta*-C from PPh_3); 129.1 (s, *para*-C from $\text{C}_6\text{H}_5^{\text{tz}}$); 128.9 (d, $^1J(\text{C},\text{P}) = 59.0$, *ipso*-C from PPh_3); 124.6 (s, *ortho*-C from $\text{C}_6\text{H}_5^{\text{tz}}$). FT-IR (ν , cm^{-1}): 3074 (w), 3051 (w), 3032 (w), $\nu(\text{CH}_{\text{aryl}})$; 1595 (m), 1500 (s), 1481 (m), 1435 (vs), 1418 (m), 1402 (m), 1377 (s), $\nu(\text{CC}_{\text{aryl}}) + \delta(\text{CH}_{\text{aryl}})$; 1330 (w), 1311 (w), 1271 (s), 1229 (s), 1182 (m), 1159 (m), $\nu(\text{N}=\text{N}_{\text{tz}}) + \nu(\text{N}-\text{N}_{\text{tz}})$; 1103 (vs), 1079 (m), 1028 (m), 998 (m), 980 (w), $\delta(\text{CN}_4) + \delta(\text{C}_6\text{H}_5)$; 758 (vs), 748 (vs), $\nu(\text{C}-\text{P})$; 713 (s), 696 (vs) $\nu(\text{C}-\text{S})$.

[1-(2-(N-Dimethylamino)ethyl)tetrazol-5-ylthiolato](triphenylphosphane)gold(I) (**2c**). Yield (from acetonitrile): 265 mg (84%). *Anal.* Calc. for $\text{C}_{23}\text{H}_{25}\text{N}_5\text{PSAu}$: C, 43.75; H, 3.99; N, 11.09; S, 5.08. Found: C, 43.72; H, 3.44; N, 11.07; S, 5.01%. MS (ESI^+ , 100 V, CH_2Cl_2 , m/z): 632.13 $[\text{M} + \text{H}]^+$; 721.15 $[\text{Au}(\text{PPh}_3)_2]^+$. DSC/TG: 195–196 °C (mp); 256 °C (T_{max} , exothermal dec.). ^1H NMR [400 MHz, CDCl_3 , δ (ppm), J (Hz)]: 7.62–7.47 (m, 15H, C_6H_5 from PPh_3); 4.41 (t, $^3J(\text{H},\text{H}) = 7.2$, 2H, $\alpha\text{-CH}_2$); 2.85 (t, $^3J(\text{H},\text{H}) = 7.2$, 2H, $\beta\text{-CH}_2$); 2.32 (s, 6H, $\text{N}(\text{CH}_3)_2$). ^{13}C NMR [100 MHz, CDCl_3 , δ (ppm), J (Hz)]: 157.6 (s, $\text{C}(5)^{\text{tz}}$);

134.3 (d, $^2J(\text{C},\text{P}) = 13.8$, *ortho*-C from PPh_3); 131.9 (d, $^4J(\text{C},\text{P}) = 2.5$, *para*-C from PPh_3); 129.3 (d, $^3J(\text{C},\text{P}) = 11.7$, *meta*-C from PPh_3); 128.9 (d, $^1J(\text{C},\text{P}) = 59.0$, *ipso*-C from PPh_3); 57.5 (s, $\alpha\text{-CH}_2$); 45.5 (s, $\text{N}(\text{CH}_3)_2$); 45.4 (s, $\beta\text{-CH}_2$). FT-IR (ν , cm^{-1}): 3067 (m), 3049 (m), $\nu(\text{CH}_{\text{aryl}})$; 2965 (s), 2940 (s), 2856 (m), 2825 (s), 2791 (m), $\nu(\text{CH}_{\text{alkyl}})$; 1585 (m), 1480 (s), $\nu(\text{CC}_{\text{aryl}})$; 1437 (vs), 1380 (s), $\delta(\text{CH}_{\text{aryl}}) + \delta(\text{CH}_{\text{alkyl}})$; 1301 (s), 1260 (m), 1250 (m), 1179 (s), 1160 (m), $\nu(\text{N}=\text{N}_{\text{tz}}) + \nu(\text{N}-\text{N}_{\text{tz}})$; 1100 (s), 1066 (m), 1023 (m), 997 (m), 982 (m), 920 (m), $\delta(\text{CN}_4) + \delta(\text{C}_6\text{H}_5)$; 777 (m), $\nu(\text{C}-\text{N})$; 750 (vs), $\nu(\text{C}-\text{P})$; 710 (s), 690 (vs) $\nu(\text{C}-\text{S})$.

Complexes **2d** and **2e** were obtained using the same procedure starting from chlorido[tri(2-furyl)phosphane]gold(I) and the corresponding 1-*R*-5-thiotetrazole ($\text{R} = \text{Me}$ (**3a**), Ph (**3b**)).

(1-Methyltetrazol-5-ylthiolato)[tri(2-furyl)phosphane]gold(I) (**2d**). Yield (from THF–hexane): 220 mg (81%). *Anal.* Calc. for $\text{C}_{14}\text{H}_{12}\text{N}_4\text{O}_3\text{PSAu}$: C, 30.89; H, 2.22; N, 10.29. Found: C, 30.97; H, 2.38; N, 10.71%. MS (ESI^+ , 100 V, CH_2Cl_2 , m/z): 545.01 $[\text{M} + \text{H}]^+$; 661.03 $[\text{Au}(\text{2-furyl})_2]^+$. DSC/TG: 120–122 °C (mp); 232 °C (T_{max} , exothermal dec.). ^1H NMR [400 MHz, CDCl_3 , δ (ppm)]: 7.80 (m, 3H, CH^{furyl}); 7.34 (m, 3H, CH^{furyl}); 6.57 (m, 3H, CH^{furyl}); 3.97 (s, 3H, CH_3). ^{13}C NMR [100 MHz, CDCl_3 , δ (ppm), J (Hz)]: 157.8 (s, $\text{C}(5)^{\text{tz}}$); 150.0 (d, $^3J(\text{C},\text{P}) = 6.4$, $\text{C}(5)$ from furyl); 141.3 (d, $^1J(\text{C},\text{P}) = 93.8$, $\text{C}(2)$ from furyl); 125.8 (d, $^2J(\text{C},\text{P}) = 27.1$, $\text{C}(3)$ from furyl); 111.7 (d, $^3J(\text{C},\text{P}) = 9.8$, $\text{C}(4)$ from furyl); 34.1 (s, CH_3). FT-IR (ν , cm^{-1}): 3115 (m), 2981 (w), $\nu(\text{CH}_{\text{aryl}})$; 2951 (w), $\nu(\text{CH}_{\text{alkyl}})$; 1546 (m), 1465 (m), 1450 (m), $\nu(\text{CC}_{\text{aryl}})$; 1381 (m), 1366 (m), $\delta(\text{CH}_{\text{aryl}}) + \delta(\text{CH}_{\text{alkyl}})$; 1271 (m), 1215 (m), $\nu(\text{N}=\text{N}_{\text{tz}}) + \nu(\text{N}-\text{N}_{\text{tz}})$; 1170 (m), $\nu(\text{C}-\text{O})$; 1130 (m), 1110 (s), 910 (m), 881 (m), $\delta(\text{CN}_4) + \delta(\text{furyl})$; 760 (s), $\nu(\text{C}-\text{P})$; 705 (m) $\nu(\text{C}-\text{S})$.

(1-Phenyltetrazol-5-ylthiolato)[tri(2-furyl)phosphane]gold(I) (**2e**). Yield (from CH_2Cl_2 –hexane): 270 mg (89%). *Anal.* Calc. for $\text{C}_{19}\text{H}_{14}\text{N}_4\text{O}_3\text{PSAu}$: C, 37.64; H, 2.33; N, 9.24. Found: C, 37.43; H, 2.27; N, 9.12%. MS (ESI^+ , 100 V, CH_2Cl_2 , m/z): 607.03 $[\text{M} + \text{H}]^+$; 661.03 $[\text{Au}(\text{2-furyl})_2]^+$. DSC/TG: 179–180 °C (mp); 214 °C (T_{max} , exothermal dec.). ^1H NMR [400 MHz, CDCl_3 , δ (ppm)]: 7.80–7.79 (m, 3H, CH^{furyl}); 7.78–7.76 (m, 2H, $\text{C}_6\text{H}_5^{\text{tz}}$); 7.54–7.51 (m, 2H, $\text{C}_6\text{H}_5^{\text{tz}}$); 7.48–7.45 (m, 1H, $\text{C}_6\text{H}_5^{\text{tz}}$); 7.34–7.32 (m, 3H, CH^{furyl}); 6.57–6.56 (m, 3H, CH^{furyl}). ^{13}C NMR [100 MHz, CDCl_3 , δ (ppm), J (Hz)]: 157.8 ($\text{C}(5)^{\text{tz}}$); 150.0 (d, $^3J(\text{C},\text{P}) = 6.3$, $\text{C}(5)$ from furyl); 141.4 (d, $^1J(\text{C},\text{P}) = 92.5$, $\text{C}(2)$ from furyl); 135.2 (s, *ipso*-C from $\text{C}_6\text{H}_5^{\text{tz}}$); 129.3 (s, *meta*-C from $\text{C}_6\text{H}_5^{\text{tz}}$); 129.2 (s, *para*-C from $\text{C}_6\text{H}_5^{\text{tz}}$); 125.7 (d, $^2J(\text{C},\text{P}) = 27.1$, $\text{C}(3)$ from furyl); 124.5 (s, *ortho*-C from $\text{C}_6\text{H}_5^{\text{tz}}$); 111.7 (d, $^3J(\text{C},\text{P}) = 9.8$, $\text{C}(4)$ from furyl). FT-IR (ν , cm^{-1}): 3158 (m), 3122 (m), $\nu(\text{CH}_{\text{aryl}})$; 1597 (m), 1550 (m), 1496 (s), $\nu(\text{CC}_{\text{aryl}})$; 1459 (m), 1397 (m), 1369 (s), $\delta(\text{CH}_{\text{aryl}})$; 1313 (m), 1266 (m), 1217 (m), $\nu(\text{NN}_{\text{tz}}) + \nu(\text{N}-\text{N}_{\text{tz}})$; 1170 (s), $\nu(\text{C}-\text{O})$; 1130 (s), 1100 (m), 1080 (m), 1040 (m), 1010 (vs), 909 (m), 881 (m), 830 (m), $\delta(\text{CN}_4) + \delta(\text{furyl})$; 752 (vs), $\nu(\text{C}-\text{P})$; 692 (s) $\nu(\text{C}-\text{S})$.

Crystallographic studies

Single crystal X-ray data of complex **2e** were collected at room temperature on a SMART APEX II diffractometer using graphite



monochromated Mo-K α radiation ($\lambda = 0.71073$ Å). The reflection data were corrected on absorption. The structures were solved by direct methods with the program SIR2004³⁷ and refined on F^2 by the full-matrix least squares technique with SHELXL-2013.³⁸ All non-hydrogen atoms were refined anisotropically. The hydrogen atoms were placed at calculated positions and refined using a “riding” model, with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$. Molecular graphics was performed with the program PLATON.³⁹ Crystallographic data of complex **2e** (excluding structure factors) have been deposited with the Cambridge Crystallographic Data Centre.

TrxR/GR inhibition assay

To determine the inhibition of TrxR and GR an established microplate reader based assay was performed with minor modifications.¹² For this purpose commercially available rat liver TrxR and baker yeast GR (both from Sigma-Aldrich) were used and diluted with distilled water to achieve concentrations of 0.4 U mL^{-1} (TrxR) and 20.0 U mL^{-1} (GR). The compounds were freshly dissolved as stock solutions in DMF. To each 25 μL aliquots of the enzyme solution, each 25 μL of potassium phosphate buffer pH 7.0 containing the compounds in graded concentrations or the vehicle (DMF) without compounds (control probe) were added and the resulting solutions (final concentration of DMF: max. 0.5% v/v) were incubated with moderate shaking for 75 min at 37 °C in a 96 well plate. To each well, 225 μL of the reaction mixture (1000 μL of the reaction mixture consisted of 500 μL potassium phosphate buffer pH 7.0, 80 μL of 100 mM EDTA solution pH 7.5, 20 μL bovine serum albumin solution 0.05%, 100 μL of 20 mM NADPH solution and 300 μL of distilled water) were added and the reaction was started by addition of 25 μL of an 20 mM ethanolic dithio-bis-2-nitrobenzoic acid (DTNB) solution. After proper mixing, the formation of 5-thio-2-nitrobenzoic acid (5-TNB) was monitored with a microplate reader (Perkin Elmer Victor X4) at 405 nm in 35 s intervals for 350 s. For each tested compound the non-interference with the assay components was confirmed by a negative control experiment using an enzyme free solution. The IC_{50} values were calculated as the concentration of the compound decreasing the enzymatic activity of the untreated control by 50% and are given as the means and error of 2–3 independent experiments.

Cell culture and cytotoxicity assay in MDA-MB-231 and HT-29 cells

The antiproliferative effects in MDA-MB-231 and HT-29 cells after 72 h (HT-29) or 96 h (MDA-MB-231) exposure to the gold complexes were evaluated using the crystal violet assay.

In short, HT-29 human colon carcinoma cells and MDA-MB-231 breast cancer cells were maintained in cell culture medium (minimum essential eagle medium supplemented with 2.2 g NaHCO_3 , 110 mg L^{-1} sodium pyruvate and 50 mg L^{-1} gentamicin sulfate adjusted to pH 7.4) containing 10% (v/v) fetal calf serum at 37 °C/5% CO_2 and passaged once a week according to standard procedures. For the experiments, the compounds were prepared freshly as stock solu-

tions in DMF and diluted with the cell culture medium to the final assay concentrations (0.1% v/v DMF). The assay procedure is described in more detail in our recent papers.^{10,40} The IC_{50} value was described as that concentration reducing the proliferation of untreated control cells by 50%.

Cellular uptake studies

Sample preparation for cellular uptake studies. The cellular uptake was measured according to a previously described procedure.³² In short, cells were grown until at least 70% confluency in 75 cm^2 cell culture flasks. Stock solutions of the gold complexes in DMF were freshly prepared and diluted with cell culture medium to the desired concentration (final DMF concentration: 0.1% v/v; final gold complex concentration: 10 μM). The cell culture medium of the cell culture flasks was replaced with 4.0 mL of the cell culture medium solutions containing the compounds and the flasks were incubated at 37 °C/5% CO_2 for 1, 4 or 8 h. The cell pellets were isolated by trypsinisation and centrifugation (room temperature, 3500g, 5 min), resuspended in double distilled water, lysed by sonication and appropriately diluted using double distilled water. An aliquot was removed for the purpose of protein quantification by the Bradford method. The determination of the gold content of the samples was performed by high resolution continuum source atomic absorption spectroscopy (see below). Results were calculated from the data of 2–3 independent experiments and are given as nmol gold per mg cellular protein.

Atomic absorption spectroscopy (AAS). Gold contents were measured with a graphite furnace high resolution continuum source atomic absorption spectrometer (contrAA®700, Analytik Jena AG) at 242.795 nm according to a recently described method with minor modifications.^{32,33} In short, to 200 μL aliquots of the diluted lysates 20 μL Triton X-100 (1%) and 20 μL ascorbic acid (1%) were added. The gold content of the samples was accessed using freshly prepared matrix-matched solutions of test compounds for calibration. Probes were injected at a volume of 25 μL into standard graphite wall tubes. The mean absorbance of triplicate injections was used throughout the study. Drying, atomization and tube cleaning steps were performed as outlined in more detail in the literature.¹⁰

Concentration dependent effects on drug resistant human leukemia cells. The following human cell line and its chemoresistant subline were used in this study: leukemic B-cell precursor (Nalm-6) and its vincristine (Nalm/VCR) resistant subline. All cell lines were cultured in RPMI 1640 supplemented with 10% fetal calf serum. Apoptotic cell death was determined by a modified cell cycle analysis, which detects DNA fragmentation at the single cell level. For the measurement of DNA fragmentation cells were seeded at a density of 1×10^5 cells mL^{-1} and treated with different concentrations of compound **2a** or **2d** (stock solutions were prepared in DMSO in these experiments). After 72 h of incubation, cells were collected by centrifugation at 300g for 5 min, washed with PBS at 4 °C, and fixed in PBS/2% (v/v) formaldehyde on ice for



30 min. After fixation, cells were incubated with ethanol-PBS (2 : 1, v/v) for 15 min, pelleted, and resuspended in PBS containing 40 µg per mL of RNase A. After incubation for 30 min at 37 °C, cells were pelleted again and finally resuspended in PBS containing 50 µg per mL of propidium iodide. Nuclear DNA fragmentation was then quantified by flow cytometric determination of hypodiploid DNA. Data were collected and analyzed using an FACScan (Becton Dickinson, Heidelberg, Germany) equipped with the CELLQuest software. Data are given in % hypoploidy (subG1), which reflects the number of apoptotic cells.

Acknowledgements

The postdoctoral fellowships for T.V.S. by German Academic Exchange Service (DAAD) and Saint Petersburg State University (12.50.1560.2013) as well as the financial support by Dr Kleist-Foundation (Berlin) are gratefully acknowledged. Mass-spectrometry was performed at the Center for Chemical Analysis and Material Research of St Petersburg State University.

References

- R. Rubbiani, B. Wahrig and I. Ott, *J. Biol. Inorg. Chem.*, 2014, **19**, 961–965.
- C. F. Shaw, *Chem. Rev.*, 1999, **99**, 2589–2600.
- I. Ott, *Coord. Chem. Rev.*, 2009, **253**, 1670–1681.
- B. Bertrand and A. Casini, *Dalton Trans.*, 2014, **43**, 4209–4219.
- E. E. Langdon-Jones and S. J. Pope, *Chem. Commun.*, 2014, **50**, 10343–10354.
- A. Bindoli, M. P. Rigobello, G. Scutari, C. Gabbiani, A. Casini and L. Messori, *Coord. Chem. Rev.*, 2009, **253**, 1692–1707.
- S. Gromer, L. D. Arscott, C. H. Williams, R. H. Schirmer and K. Becker, *J. Biol. Chem.*, 1998, **273**, 20096–20101.
- T. Zou, C. T. Lum, S. S.-Y. Chui and C.-M. Che, *Angew. Chem., Int. Ed.*, 2013, **52**, 1–5.
- O. Rackham, S. J. Nichols, P. J. Leedman, S. J. Berners-Price and A. Filipovska, *Biochem. Pharmacol.*, 2007, **74**, 992–1002.
- H. Scheffler, Y. You and I. Ott, *Polyhedron*, 2010, **29**, 66–69.
- C. P. Bagowski, Y. You, H. Scheffler, D. H. Vlecken, D. J. Schmitz and I. Ott, *Dalton Trans.*, 2009, 10799–10805.
- I. Ott, X. Qian, Y. Xu, D. H. W. Vlecken, I. J. Marques, D. Kubutat, J. Will, W. S. Sheldrick, P. Jesse, A. Prokop and C. P. Bagowski, *J. Med. Chem.*, 2009, **52**, 763–770.
- Y. Wang, M. Liu, R. Cao, W. Zhang, M. Yin, X. Xiao, Q. Liu and N. Huang, *J. Med. Chem.*, 2013, **56**, 1455–1466.
- T. Zou, C. T. Lum, C.-N. Lok, W.-P. To, K.-H. Low and C.-M. Che, *Angew. Chem., Int. Ed.*, 2014, **53**, 5810–5814.
- C. I. Yeo, K. K. Ooi, A. M. Akim, K. P. Ang, Z. A. Fairuz, S. N. Halim, S. W. Ng, H. L. Seng and E. R. Tiepink, *J. Inorg. Biochem.*, 2013, **127**, 24–38.
- W. Fiskus, N. Saba, M. Shen, M. Ghias, J. Liu, S. D. Gupta, L. Chauhan, R. Rao, S. Gunewardena, K. Schorno, C. P. Austin, K. Maddocks, J. Byrd, A. Melnick, P. Huang, A. Wiestner and K. N. Bhalla, *Cancer Res.*, 2014, **74**, 2520–2532.
- V. A. Ostrovskii, G. I. Koldobskii and R. E. Trifonov, *Comprehensive Heterocyclic Chemistry III*, Elsevier Ltd., 2008, vol. 15, pp. 257–423.
- M. Uemura, T. Suzuki, K. Nishio, M. Chikuma and S. Komeda, *Metallomics*, 2012, **4**, 686–692.
- S. Komeda, H. Takayama, T. Suzuki, A. Odani, T. Yamori and M. Chikuma, *Metallomics*, 2013, **5**, 461–468.
- T. V. Serebryanskaya, T. Yung, A. A. Bogdanov, A. Shchebet, S. A. Johnsen, A. S. Lyakhov, L. S. Ivashkevich, Z. A. Ibrahimava, T. S. Garbuzenco, T. S. Kolesnikova, N. I. Melnova, P. N. Gaponik and O. A. Ivashkevich, *J. Inorg. Biochem.*, 2013, **120**, 44–53.
- A. Ilie and K. Karaghiosoff, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2011, **186**, 389–403.
- W. Beck, K. Burger and M. Keubler, *Z. Anorg. Allg. Chem.*, 1977, **428**, 173–186.
- A. Ilie, C. I. Rat, S. Scheutzow, C. Kiske, K. Lux, T. M. Klapotke, C. Silvestru and K. Karaghiosoff, *Inorg. Chem.*, 2011, **50**, 2675–2684.
- H. Nöth, W. Beck and K. Burger, *Eur. J. Inorg. Chem.*, 1998, 93–99.
- U. Monkowius, S. Nogai and H. Schmidbaur, *Z. Naturforsch., B: Chem. Sci.*, 2003, **58**, 751–758.
- H. Schmidbaur and A. Schier, *Chem. Soc. Rev.*, 2012, **41**, 370–412.
- R. Rubbiani, S. Can, I. Kitanovic, H. Alborzinia, M. Stefanopoulou, M. Kokoschka, S. Mönchgesang, W. S. Sheldrick, S. Wölfl and I. Ott, *J. Med. Chem.*, 2011, **54**, 8646–8657.
- A.-B. Witte, K. Anestel, E. Jerremalm, H. Ehrsson and E. S. J. Arner, *Free Radicals Biol. Med.*, 2005, **39**, 696–703.
- E. S. Arner and A. Holmgren, *Eur. J. Biochem.*, 2000, **267**, 6102–6109.
- S. Schäfer, I. Ott, R. Gust and W. S. Sheldrick, *Eur. J. Inorg. Chem.*, 2007, 3034–3046.
- I. Ott, K. Schmidt, B. Kircher, P. Schumacher, T. Wiglenda and R. Gust, *J. Med. Chem.*, 2005, **48**, 622–629.
- I. Ott, H. Scheffler and R. Gust, *ChemMedChem*, 2007, **2**, 702–707.
- R. Rubbiani, I. Kitanovic, H. Alborzinia, S. Can, A. Kitanovic, L. A. Onambele, M. Stefanopoulou, Y. Geldmacher, W. S. Sheldrick, G. Wolber, A. Prokop, S. Wölfl and I. Ott, *J. Med. Chem.*, 2010, **53**, 8608–8618.
- R. Rubbiani, E. Schuh, A. Meyer, J. Lemke, J. Wimberg, N. Metzler-Nolte, F. Meyer, F. Mohr and I. Ott, *Med. Chem. Commun.*, 2013, **4**, 942–948.
- R. Rubbiani, L. Salassa, A. de Almeida, A. Casini and I. Ott, *ChemMedChem*, 2014, **9**, 1205–1210.
- M. J. McKeage, S. J. Berners-Price, P. Galettis, R. J. Bowen, W. Brouwer, L. Ding, L. Zhuang and B. C. Baguley, *Cancer Chemother. Pharmacol.*, 2000, **46**, 343–350.



- 37 M. C. Burla, R. Caliendo, M. Camalli, B. Carrozzini, G. L. Cascarano, L. D. Caro, C. Giacovazzo, G. Polidori and R. Spagna, *J. Appl. Crystallogr.*, 2005, **38**, 381–388.
- 38 G. M. Sheldrick, *Acta Crystallogr., Sect. A: Fundam. Crystallogr.*, 2008, **64**, 112–122.
- 39 A. L. Spek, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2009, **65**, 148–155.
- 40 K. Navakoski de Oliveira, V. Andermark, S. von Grafenstein, L. A. Onambele, G. Dahl, R. Rubbiani, G. Wolber, C. Gabbiani, L. Messori, A. Prokop and I. Ott, *ChemMedChem*, 2013, **8**, 256–264.

